度伐利尤单抗联合同步放疗治疗局部晚期非小细胞肺癌:DOLPHIN 2期非随机对照试验
这项在日本12家机构开展的多中心单臂2期非随机对照试验,评估度伐利尤单抗联合同步放疗及维持治疗用于PD-L1阳性、不可切除局部晚期NSCLC的疗效与安全性。可评估的35例患者12个月无进展生存率为72.1%,中位无进展生存期25.6个月,确认客观缓解率90.9%,3或4级不良事件发生率为52.9%,5级为5.9%。
要点
- 12个月无进展生存率72.1%,中位无进展生存期25.6个月,中位随访22.8个月。
- 确认客观缓解率90.9%,治疗完成率57.6%,97.1%患者完成计划放疗。
- 3或4级不良事件发生率52.9%,5级为5.9%,任何级别肺炎或放射性肺炎67.6%。
核心结论
- 作者认为度伐利尤单抗联合根治性放疗用于PD-L1阳性、不可切除局部晚期NSCLC是有前景的治疗,不良事件可耐受,适合作为3期临床试验的研究治疗。
研究设计与样本
- 多中心、单臂2期非随机对照试验,由日本12家机构于2019年9月13日至2022年5月31日开展。
- 主要注册阶段纳入74例PD-L1阳性、不可切除局部晚期NSCLC患者,本次分析可评估人群为35例。
- 干预为放疗60 Gy联合同步及维持度伐利尤单抗10 mg/kg每2周一次,最长1年。
- 主要终点为独立中心审查评估的12个月无进展生存率,采用Kaplan-Meier法估计,90%CI采用Greenwood公式计算。
主要发现
- 12个月无进展生存率为72.1%(90%CI,59.1%-85.1%),中位无进展生存期25.6个月(95%CI,13.1个月至不可估计),中位随访22.8个月(范围,4.3-31.8个月)。
- 计划放疗完成率为97.1%,确认客观缓解率为90.9%(95%CI,75.7%-98.1%),治疗完成率为57.6%(95%CI,39.2%-74.5%)。
- 安全性分析集34例中,3或4级不良事件18例(52.9%),5级2例(5.9%)。
- 任何级别肺炎或放射性肺炎23例(67.6%),3或4级4例(11.8%)。
关键数值与推荐
- 主要终点12个月无进展生存率72.1%(90%CI,59.1%-85.1%)。
- 中位无进展生存期25.6个月(95%CI,13.1个月至不可估计)。
- 确认客观缓解率90.9%(95%CI,75.7%-98.1%),治疗完成率57.6%(95%CI,39.2%-74.5%)。
- 3或4级不良事件18例(52.9%),5级2例(5.9%);任何级别肺炎或放射性肺炎23例(67.6%),3或4级4例(11.8%)。
临床怎么用
- 作者认为该方案是有前景的治疗,不良事件可耐受,适合作为3期临床试验的研究治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Administration of durvalumab after concurrent chemoradiotherapy is the standard treatment of unresectable, locally advanced non-small cell lung cancer (NSCLC); however, 20% to 30% of patients do not receive durvalumab because of adverse events (AEs) during concurrent chemoradiotherapy. In addition, radiotherapy and immunotherapy have a synergistic effect. OBJECTIVE: To investigate the efficacy and safety of durvalumab immunotherapy plus concurrent radiotherapy followed by maintenance with durvalumab therapy for treatment of locally advanced NSCLC without chemotherapy. DESIGN, SETTING, AND PARTICIPANTS: The multicenter, single-arm DOLPHIN (Phase II Study of Durvalumab [MEDI4736] Plus Concurrent Radiation Therapy in Advanced Localized NSCLC Patients) nonrandomized controlled trial was performed by 12 institutions in Japan from September 13, 2019, to May 31, 2022. Participants in the primary registration phase included 74 patients with programmed cell death ligand 1 (PD-L1)-positive, unresectable, locally advanced NSCLC. The current analyses were conducted from June 1, 2022, to October 31, 2022. INTERVENTIONS: Patients received radiotherapy (60 Gy) in combination with concurrent and maintenance durvalumab immunotherapy, 10 mg/kg every 2 weeks, for up to 1 year. MAIN OUTCOMES AND MEASURES: The primary end point of the rate of 12-month progression-free survival (PFS), as assessed by an independent central review, was estimated using the Kaplan-Meier method and evaluated with 90% CIs calculated using the Greenwood formula. The key secondary end points were PFS, objective response rate, treatment completion rate, and AEs. RESULTS: Data from 35 patients (median [range] age, 72 [44-83] years; 31 [88.6%] men) were included in the full analysis set of the evaluable population. The 12-month PFS rate was 72.1% (90% CI, 59.1%-85.1%), and the median PFS was 25.6 months (95% CI, 13.1 months to not estimable) at a median follow-up of 22.8 months (range, 4.3-31.8 months). Scheduled radiation therapy was completed in 97.1% of patients. The confirmed objective response rate was 90.9% (95% CI, 75.7%-98.1%), and the treatment completion rate was 57.6% (95% CI, 39.2%-74.5%). Among 34 patients evaluated in the safety analysis set, AEs of grade 3 or 4 occurred in 18 patients (52.9%), and of grade 5 in 2 patients (5.9%). Pneumonitis or radiation pneumonitis of any grade occurred in 23 patients (67.6%), and of grades 3 or 4 in 4 patients (11.8%). CONCLUSIONS AND RELEVANCE: Findings from this phase 2 nonrandomized controlled trial indicate that durvalumab immunotherapy combined with curative radiotherapy for patients with PD-L1-positive, unresectable, locally advanced NSCLC is a promising treatment with tolerable AEs and is appropriate as a study treatment for phase 3 clinical trials. TRIAL REGISTRATION: Japan Registry of Clinical Trials ID: jRCT2080224763.
引用
- Tachihara M, Tsujino K, Ishihara T, et al. Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial. JAMA Oncol. 2023. PMID: 37676681. doi:10.1001/jamaoncol.2023.3309
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。